Has Jean Pierre Lindenmayer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,621 in general payments to Jean Pierre Lindenmayer, MD across 17 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jean Pierre Lindenmayer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jean Pierre Lindenmayer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jean Pierre Lindenmayer, MD

Psychiatry · New York, NYNPI 1871652958

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,734 of the $7,621 with a category attached, or 88.4%. 9 manufacturers reported payments, led by Aurobindo Pharma USA, Inc. at 40.3% of the total. Reporting peaked in 2024 at $3,276 and has fallen 77.9% since, to $724 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,621in general payments, 2019–2025

Across 17 payments — averaging $448.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Aurobindo Pharma USA, Inc.$3K
Jazz Pharmaceuticals Inc.$2K
Alkermes, Inc.$1K
Neurocrine Biosciences, Inc.$743
Mylan Inc.$648
Otsuka America Pharmaceutical, Inc.$323
plus $258 from 3 others

$849,579in research payments, 2019–2025

Across 150 payments — averaging $5663.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Hoffmann-la Roche Limited$199K
Takeda Pharmaceuticals U.S.A., Inc.$173K
E.r. Squibb & Sons, L.L.C.$127K
Roche TCRC, Inc.$123K
GW Research Limited$74K
Otsuka Pharmaceutical Development & Commercialization, Inc.$42K
plus $111K from 6 others

What the payments were for

Consulting fees$6,73488%
Speaking & faculty fees$1081%
Food & beverage$76710%
Education$130%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Aurobindo Pharma USA, Inc.	1	$3,073
Jazz Pharmaceuticals Inc.	1	$1,563
Alkermes, Inc.	2	$1,013
Neurocrine Biosciences, Inc.	4	$743
Mylan Inc.	1	$648
Otsuka America Pharmaceutical, Inc.	3	$323
Otsuka Pharmaceutical Development & Commercialization, Inc.	2	$108
E.r. Squibb & Sons, L.L.C.	2	$76
Teva Pharmaceuticals USA, Inc.	1	$74

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Clozapine$3,721
SUNOSI$1,563
REXULTI$250
INGREZZA$166

How this compares

$7,621 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Medicare billing

Part B allowed, 2024

$14,747

Medicare patients

Services billed

176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Aripiprazole	11	$7,430
Duloxetine Hcl	29	$533
Bupropion Hcl	18	$443
Venlafaxine Hcl ErVenlafaxine Hcl	17	$409
Bupropion Hcl SrBupropion Hcl	14	$385
Pramipexole DihydrochloridePramipexole Di-Hcl	13	$217
Fluoxetine Hcl	13	$134
Memantine Hcl	12	$132
Lorazepam	22	$125
Trazodone Hcl	13	$104
Clonazepam	11	$95
Metformin Hcl ErMetformin Hcl	16	$22
Zolpidem Tartrate	17	$13

Paid to pharmacies, not to this prescriber.

Other psychiatry in New York

Manish ZinzuvadiaNew York$1.3M
Jianping ChenNew York$1.2M
Ulla Kristina LaaksoNew York$890K
Kerry SulkowiczNew York$435K
Ralph AquilaNew York$143K
Daniel KarlinNew York$101K
David StraussNew York$95K
Anissa Abi-DarghamNew York$94K
Robin McGarryNew York$69K
Nicole AllenNew York$63K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →